Abstract
Background
Multi-visceral resection often is used in the treatment of retroperitoneal sarcoma (RPS). The morbidity after distal pancreatectomy for primary pancreatic cancer is well-documented, but the outcomes after distal pancreatectomy for primary RPS are not. This study aimed to evaluate morbidity and oncologic outcomes after distal pancreatectomy for primary RPS.
Methods
In this study, 26 sarcoma centers that are members of the Trans-Atlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG) retrospectively identified consecutive patients who underwent distal pancreatectomy for primary RPS from 2008 to 2017. The outcomes measured were 90-day severe complications (Clavien-Dindo ≥ 3), postoperative pancreatic fistula (POPF) rate, and oncologic outcomes.
Results
Between 2008 and 2017, 280 patients underwent distal pancreatectomy for primary RPS. The median tumor size was 25 cm, and the median number of organs resected, including the pancreas, was three. In 96% of the operations, R0/R1 resection was achieved. The 90-day severe complication rate was 40 %. The grades B and C POPF complication rates were respectively 19% and 5% and not associated with worse overall survival. Administration of preoperative radiation and factors to mitigate POPF did not have an impact on the risk for the development of a POPF. The RPS invaded the pancreas in 38% of the patients, and local recurrence was doubled for the patients who had a microscopic, positive pancreas margin (hazard ratio, 2.0; p = 0.042).
Conclusion
Distal pancreatectomy for primary RPS has acceptable morbidity and oncologic outcomes and is a reasonable approach to facilitate complete tumor resection.
Similar content being viewed by others
Change history
17 March 2022
A Correction to this paper has been published: https://doi.org/10.1245/s10434-022-11599-w
References
Kleeff J, et al. Distal pancreatectomy: risk factors for surgical failure in 302 consecutive cases. Ann Surg. 2007;245:573–82.
Lillemoe KD, et al. Distal pancreatectomy: indications and outcomes in 235 patients. Ann Surg. 1999;229:693–8; discussion 698–700.
Reeh M, et al. High surgical morbidity following distal pancreatectomy: still an unsolved problem. World J Surg. 2011;35:1110–7.
Ecker BL, et al. Risk factors and mitigation strategies for pancreatic fistula after distal pancreatectomy: analysis of 2026 resections from the International, Multi-institutional Distal Pancreatectomy Study Group. Ann Surg. 2019;269:143–9.
Gronchi A, et al. Variability in patterns of recurrence after resection of primary retroperitoneal sarcoma (RPS): a report on 1007 patients from the Multi-Institutional Collaborative RPS Working Group. Ann Surg. 2016;263:1002–9.
Tseng WW, Pollock RE, Gronchi A. The Trans-Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG): “red wine or white”? Ann Surg Oncol. 2016;23:4418–20.
MacNeill AJ, et al. Postoperative morbidity after radical resection of primary retroperitoneal sarcoma: a report from the Transatlantic RPS Working Group. Ann Surg. 2018;267:959–64.
Trans-Atlantic Retroperitoneal Sarcoma Working Group. Management of metastatic retroperitoneal sarcoma: a consensus approach from the Trans-Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG). Ann Oncol. 2018;29:857–71.
van Houdt WJ, et al. New research strategies in retroperitoneal sarcoma: the case of TARPSWG, STRASS, and RESAR: making progress through collaboration. Curr Opin Oncol. 2019;31:310–6.
Raut CP, et al. Predicting survival in patients undergoing resection for locally recurrent retroperitoneal sarcoma: a study and novel nomogram from TARPSWG. Clin Cancer Res. 2019;25:2664–71.
Haas RLM, et al. Radiotherapy for retroperitoneal liposarcoma: a report from the Transatlantic Retroperitoneal Sarcoma Working Group. Cancer. 2019;125:1290–300.
Bassi C, et al. (2017) The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 years after. Surgery. 2017;161:584–91.
Keung EZ, et al. Postoperative pancreatic fistula after distal pancreatectomy for non-pancreas retroperitoneal tumor resection. Am J Surg. 2020;220:140–6.
Miao Y, et al. Management of the pancreatic transection plane after left (distal) pancreatectomy: expert consensus guidelines by the International Study Group of Pancreatic Surgery (ISGPS). Surgery. 2020.
Fairweather M, et al. Incidence and adverse prognostic implications of histopathologic organ invasion in primary retroperitoneal sarcoma. J Am Coll Surg. 2017;224:876–83.
Toulmonde M, et al. Retroperitoneal sarcomas: patterns of care at diagnosis, prognostic factors, and focus on main histological subtypes: a multicenter analysis of the French Sarcoma Group. Ann Oncol. 2014;25:735–42.
Berselli M, et al. Morbidity of left pancreatectomy when associated with multivisceral resection for abdominal mesenchymal neoplasms. JOP. 2011;12:138–44.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosure
Giovanni Grignani received grants from PharmaMar, Novartis, and Bayer and was a consultant for Novartis, Bayer, Pharmamar, EISAI, Lilly, and Merck. Piotr Rutkowski received honoraria from MSD, Bristol Myers Squibb, Novartis, Pierre Fabre, Amgen, Sanofi, Merck, Roche, and Blueprint Medicines. Sylvie Bonvalot received honoraria from Nanobiotix and Pharmamar. Nita Ahuja received funding from Astex on developing therapeutics for sarcomas.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Presented at the Society of Surgical Oncology, 2020, and the International Conference on Surgical Cancer Care, August 2020, Boston, MA, USA.
The original online version of this article was revised: Elisabetta Pennacchioli's affiliation was corrected.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Bagaria, S.P., Swallow, C., Suraweera, H. et al. Morbidity and Outcomes After Distal Pancreatectomy for Primary Retroperitoneal Sarcoma: An Analysis by the Trans-Atlantic Australasian Retroperitoneal Sarcoma Working Group. Ann Surg Oncol 28, 6882–6889 (2021). https://doi.org/10.1245/s10434-021-09739-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-021-09739-9